Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B

Table 10 Changes in serum HA, LM, P-III-P and IV-C contents (mean±SD).

Parameter	Group	n	Pretreatment	12 wk of treatment	24 wk of treatment
HA (mg/L)	Experimental	110	303.6±235.7	178.9±158.0b	147.9±131.3b
	Control	106	276.3±234.9	258.9±243.2a	261.8±253.6b
LM (mg/L)	Trial	110	137.0±84.6	127.5±92.7a	122.4±96.5b
	Control	106	134.1±98.6	128.4±55.7	121.2±48.9
P-III-P (mg/L)	Experimental	110	11.1±5.0	8.8±4.9b	7.4±4.4b
	Control	106	9.6±5.6	9.7±6.6	9.4±6.9
IV-C (mg/L)	Trial	110	119.1±132.5	74.5±88.4b	64.5±82.5b
	Control	106	91.8±76.7	71.4±57.8	62.4±54.7b

^aP<0.05,

^bP<0.01 vs the same group.